Literature DB >> 3325875

Elevated expression of an exogenous c-myc gene is insufficient for transformation and tumorigenic conversion of established fibroblasts.

M Zerlin1, M A Julius, C Cerni, K B Marcu.   

Abstract

Two established rat fibroblast lines, differing only by their number of generations in culture, show dramatically different responses to the elevated c-myc expression delivered by an efficient murine c-myc retrovirus vector. Thus, a late passage (60 generation) FR3T3 line acquires a transformed and tumorigenic phenotype upon introduction of this activated c-myc gene as indicated by its altered morphology, high efficiency of focus formation, soft agar clonability, saturation density in monolayer culture, and short latency of tumorigenicity in syngeneic hosts. Remarkably, none of these characteristics, except for an increased refractility in monolayers and an epidermal growth factor (EGF)-dependent agar clonability, were observed in a variety of early passage (10 generation) FR3T3 c-myc clones. BALB/c A31 fibroblasts transfected with this c-myc retroviral vector behaved essentially the same as the FR3T3 early line except for their inability to grow in suspension in response to EGF. However, transformation and tumorigenic conversion of each of these three fibroblast lines was achieved by an activated ras oncogene. Hence, elevated c-myc expression is insufficient for transformation of established fibroblasts but depends upon other acquired cooperating functions which are not necessary for ras induced transformation. We also demonstrate that endogenous c-myc expression remains unaffected even in clones expressing a 100-fold excess of exogenous c-myc RNAs demonstrating that c-myc autoregulation is not operative in these cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325875

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Cellular oncogenes in neoplasia.

Authors:  V T Chan; J O McGee
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

2.  Host range restrictions of oncogenes: myc genes transform avian but not mammalian cells and mht/raf genes transform mammalian but not avian cells.

Authors:  R Li; R P Zhou; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts.

Authors:  C Cerni; B Binétruy; J T Schiller; D R Lowy; G Meneguzzi; F Cuzin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Negative autoregulation of c-myc transcription.

Authors:  L J Penn; M W Brooks; E M Laufer; H Land
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

5.  Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc.

Authors:  Li Sheng-Fowler; Fang Cai; Haiqing Fu; Yong Zhu; Brian Orrison; Gideon Foseh; Don G Blair; Stephen H Hughes; John M Coffin; Andrew M Lewis; Keith Peden
Journal:  Int J Biol Sci       Date:  2010-03-29       Impact factor: 6.580

6.  Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene.

Authors:  J Schütte; J D Minna; M J Birrer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

7.  Negative autoregulation of c-myc gene expression is inactivated in transformed cells.

Authors:  F Grignani; L Lombardi; G Inghirami; L Sternas; K Cechova; R Dalla-Favera
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

8.  A mouse strain defective in both T cells and NK cells has enhanced sensitivity to tumor induction by plasmid DNA expressing both activated H-Ras and c-Myc.

Authors:  Li Sheng-Fowler; Wei Tu; Haiqing Fu; Haruhiko Murata; Lynda Lanning; Gideon Foseh; Juliete Macauley; Donald Blair; Stephen H Hughes; John M Coffin; Andrew M Lewis; Keith Peden
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.